Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%

Ophthalmology

Volumn 111, Issue 8, 2004, Pages 1480-1488

  McCarey, Bernard E ^a,b   Kapik, Barry M ^b   Kane, Frances E ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Novartis Ophthalmics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAXOLOL; BIMATOPROST; LATANOPROST; TIMOLOL MALEATE; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; EYE DROPS; PROSTAGLANDIN F2 ALPHA; TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EYE COLOR; EYE PHOTOGRAPHY; EYELASH; FEMALE; HUMAN; HYPERPIGMENTATION; INCIDENCE; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PIGMENTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HAIR COLOR; INTRAOCULAR PRESSURE; IRIS; MIDDLE AGED; MULTICENTER STUDY; PHOTOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BETAXOLOL; DINOPROST; DOUBLE-BLIND METHOD; EYE COLOR; EYELASHES; FEMALE; GLAUCOMA, OPEN-ANGLE; HAIR COLOR; HUMANS; HYPERPIGMENTATION; INCIDENCE; INTRAOCULAR PRESSURE; IRIS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PHOTOGRAPHY; TIMOLOL;

EID: 3442880151     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2003.11.013     Document Type: Article

References (43)

1. Physicians' Desk Reference for Ophthalmic Medicines 2002. 29th ed. Montvale, NJ: Medical Economics Co.; 2000:315-7
2. Physicians' Desk Reference for Ophthalmic Medicines 2001. 30th ed. Montvale, NJ: Medical Economics Co.; 2001:221
3. Physicians' Desk Reference for Ophthalmic Medicines 2001. 30th ed. Montvale, NJ: Medical Economics Co.; 2001:240
4. Sharif N.A., Williams G.W., Kelly C.R. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol. 432:2001;211-213
5. Davies S.S., Ju W.K., Neufeld A.H., et al. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther. 19:2003;45-54
6. Physicians' Desk Reference for Ophthalmic Medicines 2002. 30th ed. Montvale, NJ: Medical Economics Co.; 2001:306
7. Bhattacherjee P., Paterson C.A., Percicot C. Studies on receptor binding and signal transduction pathways of unoprostone isopropyl. J Ocul Pharmacol Ther. 17:2001;433-441
8. Taniguchi T., Haque M.S., Sugiyama K., et al. Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits. J Ocul Pharmacol Ther. 12:1996;489-498
9. Yoshida S., Deguchi T., Osama H., Ueno R. The mechanism of IOP lowering action of Rescula, a new therapeutic agent for glaucoma and ocular hypertension in various animals - comparison with prostaglandin F2 alpha. Kiso Rinsho (Clin Rep). 28:1994;3827-3838
10. Yuguchi M. Ocular hypotensive action of isopropyl unoprostone. J Eye (Atarashii Ganka). 15:1998;987-990
11. Thieme H., Stumpff F., Ottlecz A., et al. Mechanisms of action of unoprostone on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 42:2001;3193-3201
12. Selén G., Stjernschantz J., Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol. 41:(suppl):1997;S125-S128
13. Susanna R. Jr, Giampani J. Jr, Borges A.S., et al. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 108:2001;259-263
14. Camras C.B. United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma a six-month masked, multicenter trial in the United States. Ophthalmology. 103:1996;138-147
15. Alm A., Stjernschantz J. Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology. 102:1995;1743-1752
16. Watson P., Stjernschantz J. Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 103:1996;126-137
17. Mastropasqua L., Carpineto P., Ciancaglini M., Gallenga P.E. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology. 106:1999;550-555
18. Travoprost Study Group, Netland P.A., Landry T., Sullivan E.K., et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 132:2001;472-484
19. International Travoprost Study Group, Goldberg I., Cunha-Vaz J., Jakobsen J.E., et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 10:2001;414-422
20. Brandt J.D., VanDenburgh A.M., Chen K., Whitcup S.M. Bimatoprost Study Group. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP a 3-month clinical trial. Ophthalmology. 108:2001;1023-1031., discussion 1032
21. Sorbera L.A., Leeson P.A., Rabasseda X., Castañer J. Bimatoprost antiglaucoma. Drugs Future. 26:2001;433-439
22. Alm A., Widengard I. Latanoprost experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand. 78:2000;71-76
23. Watson P.G. Latanoprost Study Group. Latanoprost. Two years' experience of its use in the United Kingdom. Ophthalmology. 105:1998;82-87
24. Wistrand P.J., Stjernschantz J., Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 41:(suppl):1997;S129-S138
25. Wand M. Latanoprost and hyperpigmentation of eyelashes. [letter] Arch Ophthalmol. 115:1997;1206-1208
26. Mansberger S.L., Cioffi G.A. Eyelash formation secondary to latanoprost treatment in a patient with alopecia. Arch Ophthalmol. 118:2000;718-719
27. Johnstone M.A. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 124:1997;544-547
28. Yamamoto T., Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma. 6:1997;430-432
29. Unoprostone Monotherapy Study Group-EU, Nordmann J.P., Mertz B., Yannoulis N.C., et al. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am J Ophthalmol. 133:2002;1-10
30. Camras C.B., Neely D.G., Weiss E.L. Latanoprost-induced iris color darkening a case report with long-term follow-up. J Glaucoma. 9:2000;95-98
31. Imesch P.D., Wallow I.H., Albert D.M. The color of the human eye a review of morphologic correlates and of some conditions that affect iridial pigmentation. Surv Ophthalmol. 41:(suppl):1997;S117-S123
32. Prota G., Hu D.N., Vincensi M.R., et al. Characterization of melanins in human irides and cultured uveal melanocytes from eyes of different colors. Exp Eye Res. 67:1998;293-299
33. Wilkerson C.L., Syed N.A., Fisher M.R., et al. Melanocytes and iris color. Light microscopic findings. Arch Ophthalmol. 114:1996;437-442
34. Bennett D.C. Genetics, development, and malignancy of melanocytes. Int Rev Cytol. 146:1993;191-260
35. Menon I.A., Basu P.K., Persad S., et al. Is there any difference in the photobiological properties of melanins isolated from human blue and brown eyes? Br J Ophthalmol. 71:1987;549-552
36. Drago F., Marino A., La Manna C. Alpha-methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro. Exp Eye Res. 68:1999;85-90
37. Dutkiewicz R., Albert D.M., Levin L.A. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res. 70:2000;563-569
38. Hu D.N., Stjernschantz J., McCormick S.A. Effect of prostaglandins A(2), E(1), F(2 alpha) and latanoprost on cultured human iridal melanocytes. Exp Eye Res. 70:2000;113-120
39. Kashiwagi K., Tsukamoto K., Wakamatsu K., et al. Effects of isopropyl unoprostone on melanogenesis in mouse epidermal melanocytes. Jpn J Ophthalmol. 453:2001;259-263
40. Ozeki H., Ito S., Wakamatsu K., Ishiguro I. Chemical characterization of pheomelanogenesis starting from dihydroxyphenylalanine or tyrosine and cysteine. Effects of tyrosinase and cysteine concentrations and reaction time. Biochim Biophys Acta. 1336:1997;539-548
41. Rubin P.A., Rumelt S. Disorders of the eyelashes and eyebrows. Albert D.M., Jakobiec J.A. Principles and Practice of Ophthalmology. 2nd ed :2000;3496-3508 WB Saunders, Philadelphia
42. Records R.E. Eyebrows and eyelids. Records R.E. Physiology of the Human Eye and Visual System. 1979;9-10 Harper & Row, Hagerstown, MD
43. Moses R.A. Adler's Physiology of the Eye Clinical Application. 5th ed :1970;CV Mosby, St. Louis. 1-3